Sustainability | May 20, 2022
Pharma companies with ESG more valuable say investors
When asked how to balance ESG with broader business goals, the panel was unanimous in its assessment that ESG is ‘good for business’
When asked how to balance ESG with broader business goals, the panel was unanimous in its assessment that ESG is ‘good for business’
First disclosure from PILOT study of Breyanzi in second-line large B-cell lymphoma underscores important role of cell therapy earlier in treatment paradigm
The partnership will further strengthen Olympus leadership in the diagnosis and staging of liver disease
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection
Leading pharma companies are achieving rapid, large-scale performance improvements using a multifaceted approach that realizes short-term gains & builds long-term capabilities at the same time
A post approval change order is often necessary, but innovators should plan and prepare for this pre-approval. Planning alongside outsourcing partners will help ensure that only a small-scale study is needed—not a new full clinical study
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
This new fund is amongst the largest for the sector in India
Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer Ingelheim’s leadership in lung fibrosis and will be further investigated in a phase III clinical trial program
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
Subscribe To Our Newsletter & Stay Updated
